Beta-catenin by IHC

Alphabetical Test listing

Beta-catenin by IHC-12376 - Technical only, 12379 - Technical & interpretation

Beta-catenin by IHC
12376 - Technical only, 12379 - Technical & interpretation
  • All IHC stains will include a positive control tissue
  • Beta-catenin nuclear staining is seen in a very limited subset of mesenchymal tumor types, including desmoid-type fibromatosis (71% of cases), solitary fibrous tumor (40%), endometrial stromal sarcoma (40%) and synovial sarcoma (28%)
  • Beta-catenin can be used to separate sclerosing mesenteritis and GIST from fibromatosis. In one study, beta-catenin detected in 9 of 10 fibromatoses, including one case associated with familial adenomatous polyposis; none of the sclerosing mesenteritis or GIST cases had nuclear catenin
  • In patients with CUC, the combination of strong p53 expression and absent or weak beta catenin expression is evidence in favor of a CUC-associated polypoid dysplastic lesion in diagnostically difficult lesions
  • Beta-catenin expression is seen in fibromatosis of the breast, and in the stromal component of phyllodes tumors
  • Aberrant beta-catenin expression is often observed in metaplastic breast carcinomas
  • Beta-catenin may be seen in high grade sarcomas, where it is thought to act as an oncoprotein with intracytoplasmic and nuclear localization with binding to nuclear DNA

Submit a formalin-fixed, paraffin embedded tissue block


Formalin-fixed, paraffin embedded (FFPE) tissue block


Tissue section mounted on a charged, unstained slide


Ambient (preferred)

  • Unlabeled/mislabeled block
  • Insufficient tissue
  • Slides broken beyond repair
AHL - Immunohistochemistry
Mo - Fr
1 - 2 days

Immunohistochemical staining and microscopic examination


If requested, an interpretive report will be provided



  • Beta-catenin is an intracellular protein that is regulated by the APC protein
  • Mutations of either the APC gene or the beta-catenin gene can result in the nuclear accumulation of beta-catenin protein
  • Fibromatoses typically have mutations in the APC/beta-catenin pathway and hence have abnormal nuclear accumulation of beta-catenin protein

 Staining patterns

  • Strong nuclear staining with variable cytoplasmic staining


  1. Montgomery E et al: Beta-Catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am J Surg Pathol. 26(10): 1296-1301, 2002.
  2. Walsh et al p53 and Beta catenin expression in chronic ulcerative colitis-associated polypoid dysplasia and sporadic adenomas: an immunohistochemical study. Am J Surg Pathol. August 1999 - Volume 23 - Issue 8 - p 963.
  3. Geyer et al: Beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Modern Pathology (2011) 24, 209-231.
  4. Lacroix-Triki et al: Beta-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast Modern Pathology (2010) 23, 1438-1448.
  5. Kuhnen et al: Beta-catenin in soft tissue sarcomas: expression is related to proliferative activity in high-grade sarcomas. Mod Pathol 2000;13(9):1005-1013.
  6. Ng TL, Gown, A et al: Nuclear beta-catenin in mesenchymal tumors. Modern Pathology (2005) 18, 68-74.
88342 - 1st stain
88341 - each additional stain